Quarterly report · Q1
4572.TEDINET S100QP76
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥227m | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥555m | 2022-01-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥506m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥1m | 2022-01-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥513m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5m | 2022-01-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥514m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥11m | 2022-01-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥4.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥547m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.5bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-32.78 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.12 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 88.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥570m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥64m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥108m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥109m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 304
| Item | Context | Value | Unit |
|---|---|---|---|
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)(注) 1 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)自己保有株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準的となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes equity quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |